Literature DB >> 28009306

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.

Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón-Montaño, Tobias Koolmeister, Philip M Reaper, Oliver Mortusewicz, Sylvain A Jacques, Raoul V Kuiper, Niklas Schultz, Martin Scobie, Peter A Charlton, John R Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday.   

Abstract

Entities:  

Year:  2016        PMID: 28009306      PMCID: PMC5638787          DOI: 10.1016/j.celrep.2016.12.031

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


× No keyword cloud information.
(Cell Reports 14, 298–309; January 12, 2016) In the originally published version of this paper, there were errors in Figures 1, 6, S2, and S6. These errors have since been corrected in the updated versions of the paper and supplemental PDF that are now available online, and they are described in detail below. In Figure 1F, quantitative data of DMSO and VE-821 were incorrectly presented. In addition, in the first panel of Figure 6A, the wrong ToPro image was displayed by mistake. The figures have been corrected and now appear with the paper online. These corrections do not change the conclusions of the study in any way. DMSO and VE-821 treatment images were the same for both Figures 1B and S2A and Figures 1E and S2C. There was also a mis-insertion in Figure S2C. While microscopic images for cells treated with 30 nM of AD7762 alone or in combination with VE-821 were displayed in the main figure (Figure 1B, second and fourth panel), a higher concentration of 60 nM of AZD7762 alone or with VE-821 was displayed in Figure S2A. Displaying this additional data in the supplemental figure together with the same DMSO control and VE-821 treated images as shown in Figures 1B and 1E could confuse readers. Moreover, we think it was inappropriate to present data twice even though the data originated from the same experiment, so we have replaced the DMSO and VE-821 images in Figures S2A and S2C. Lastly, the FACS data in Figure 4A and the first three FACS plots in the upper panel of Figure S6A were the same, as we originally wanted to extend the data for Figure 4 and show more treatments in Figure S6A. We have since removed the 24 hr timepoint from Figure S6A in order to avoid repetition. The following conflict of interest should have been included in the Acknowledgments section: “Vertex Pharmaceuticals has applied for a patent where Thomas Helleday and Kumar Sanjiv are listed as inventors (patent numbers WO2015195740 & US2015359797).” These corrections do not change the conclusions of the study in any way, and the authors regret the errors. (corrected) (original) (corrected) (original) (corrected) (original) (corrected) (original)
  14 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 2.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.

Authors:  Panagiotis Kotsantis; Eva Petermann; Simon J Boulton
Journal:  Cancer Discov       Date:  2018-04-13       Impact factor: 39.397

Review 3.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

Review 4.  Targeting DNA repair and replication stress in the treatment of ovarian cancer.

Authors:  Junko Murai
Journal:  Int J Clin Oncol       Date:  2017-06-22       Impact factor: 3.402

5.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27

6.  Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.

Authors:  Fabian Schuler; Johannes G Weiss; Silke E Lindner; Michael Lohmüller; Sebastian Herzog; Simon F Spiegl; Philipp Menke; Stephan Geley; Verena Labi; Andreas Villunger
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

Review 7.  Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.

Authors:  Alessandra Ferri; Venturina Stagni; Daniela Barilà
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

Review 8.  Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.

Authors:  Anna Minchom; Caterina Aversa; Juanita Lopez
Journal:  Ther Adv Med Oncol       Date:  2018-07-13       Impact factor: 8.168

9.  Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Authors:  Juan Jin; Hehui Fang; Fang Yang; Wenfei Ji; Nan Guan; Zijia Sun; Yaqin Shi; Guohua Zhou; Xiaoxiang Guan
Journal:  Neoplasia       Date:  2018-03-30       Impact factor: 5.715

10.  Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs.

Authors:  Jing Zhang; Li Jing; Subee Tan; Er-Ming Zeng; Yingbo Lin; Lingfeng He; Zhigang Hu; Jianping Liu; Zhigang Guo
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.